Boston Scientific Corporation (BSX) faces a drastic stock decline of over 17% due to disappointing earnings guidance and revelations of misleading investor statements regarding its U.S. Electrophysiology segment. The company's stock drop was exacerbated by reports of higher-than-expected stroke risks linked to its WATCHMAN device and a downgrade from analysts, raising serious concerns about its growth trajectory. Additionally, the firm is now contending with a class-action lawsuit for misrepresentation, further shaking investor confidence despite strong long-term projections and an FDA clearance for a new product.
“Stocks making the biggest moves midday: Fannie Mae, Boston Scientific, Blackstone, Palo Alto Networks and more”
“医療機器のボストン・サイエンティフィックが大幅安 同社のペースメーカー用バッテリーに問題と伝わる - 株探 https://t.co/Q0OaT6UJ0u $BSX 9％安 https://t.co/Up6haunesZ”
“SIGNAL LIMITED: $BSX trade-around position. Sell the news reaction.”
“Nuance: Higher-than-expected stroke risk.”
“Conclusion: Data supports long-term adoption, but near-term reaction is selling.”
“$BSX - Boston Scientific receives FDA clearance for the Asurys™ Fluid Management System .”
“Sell the news reaction. ...Conclusion: Data supports long-term adoption, but near-term reaction is selling.”
“WATCHMAN data: • Met primary endpoints • 45% reduction in bleeding vs NOACs • Non-inferior efficacy ...Conclusion: Data supports long-term adoption”
“The Complaint alleges that, throughout the relevant period, Defendants made materially false and misleading statements and/or failed to disclose that: (3) the Company was experiencing material adverse trends affecting procedure volumes, increasing competitive pressures, and regulatory and reimbursement headwinds that were negatively impacting the U.S. EP segment;”
“Defendants’ repeated statements expressing confidence in the U.S. EP division’s growth trajectory, competitive positioning, and contribution to overall net income lacked a reasonable basis;”
“Defendants’ positive statements regarding the sustainability of growth in key product segments and their repeated upward revisions to full‑year guidance were materially false and misleading.”
“TOP LOSERS: Boston Scientific (BSX [https://seekingalpha.com/symbol/BSX]) -10.47%”
